SMAD2

Across TCGA pan-cancer cohorts, SMAD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMAD2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMAD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMAD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where SMAD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	13	view →
PDAC	OS	Quartile	III,IV	0.259	0.568	.008	8	view →
UCEC	DFS	Tertile	III,IV	1.000	0.518	.049	4	view →
LSCC	OS	Median	All	0.881	0.747	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMAD2–CCRCC (OS)

Open the CCRCC breakdown →